ProKidney Corp.
ProKidney Corp., a clinical-stage biotechnology, engages in developing cellular therapy candidates. It is developing Renal Autologous Cell Therapy, an autologous homologous cell admixture that is in a Phase III development program, as well as Phase II cl…
Biotechnology
US, Winston-Salem [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 77.61 | -0.49 | -2.17 | |
| Graham Fair Price | 26.34 | 7.94 | 6.28 | |
| PEG | -34.64 | -0.04 | 0.06 | |
| Price/Book | 7.89 | -0.09 | -0.10 | |
| Price/Cash Flow | 30.73 | -2.74 | -3.95 | |
| Prices/Earnings | 45.05 | -2.57 | -4.67 | |
| Price/Sales | inf | 0.00 | 23.72 | |
| Price/FCF | 30.73 | -2.74 | -3.95 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | inf | 0.00 | 0.77 | |
| Operating Margin | inf | 0.00 | -5.39 | |
| ROA | -80.58 | -0.02 | -0.01 | |
| ROE | < 0.005 | < 0.005 | 67.61 | |
| ROIC | 0.03 | 0.04 | 45.85 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.35 | 0.58 | -40.38 | |
| Dividends QOQ | 0.00 | 0.00 | 0.00 | |
| EBIT QOQ | 0.20 | -0.66 | 235.18 | |
| EPS QOQ | 0.81 | -0.68 | -15.92 | |
| FCF QOQ | 0.48 | -0.32 | -32.98 | |
| Revenue QOQ | 0.00 | -1.00 | -100.00 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 0.00 | 0.00 | 0.00 | |
| Days Sales Outstanding (DSO) | 27.54 | 0.00 | inf | |
| Inventory Turnover | 0.00 | 0.00 | 0.00 | |
| Debt/Capitalization | < 0.005 | < 0.005 | -35.95 | |
| Quick Ratio | 14.55 | 17.14 | 17.82 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Weak
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -18.43 | -17.98 | 2.41 | |
| Cash | 6.06 | 5.40 | -10.95 | |
| Capex | -0.03 | -0.02 | 40.00 | |
| Free Cash Flow | -0.45 | -0.58 | -29.77 | |
| Revenue | 0.08 | 0.00 | inf | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad